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Formation of a stable thrombus in vivo depends on the interaction between fibrinogen and 
the transglutaminase factor XIII (FXIII). Characteristics of blood plasma, such as concentration 
of Ca2+, are well known to regulate the activation and subsequent reactivity of FXIII. Despite 
this knowledge, the role fibrin(ogen) plays in modulating FXIII activation and reactivity is not 
entirely delineated. Currently, the coagulation substrate fibrinogen Aα is proposed to contain a 
binding site for the active factor XIII with fibrinogen Aα E396 serving a major role.  
A series of mass spectrometry and NMR spectroscopy studies was conducted to assess 
whether putative interactions between residues 389-403 within Fbg Aα and FXIII influence the 
ability of FXIII A2
* to crosslink reactive residues within recombinant Fbg αA 233-425. Results 
indicate the electrostatic interaction of Fbg αA E396 with FXIII does not appreciably influence 
either the activation of FXIII A2 to FXIII A2
* or the ability of FXIII A2
* to recognize and bind to 












The circulatory system possesses the capability to self-heal. Proper and timely thrombosis 
prevents continued blood loss and maintains hemostasis within the human body. Abnormal blood 
clotting may result from one or more variations in the biochemical mechanism of coagulation. 
Disorders of coagulation can be acquired or hereditary. Most inheritable coagulopathies result 
from either autosomal or X-linked mutations that encode deficiency in or nonfunctional versions 
of the proteins involved in coagulation. The most common coagulation disorders inherited in 
humans include von Willebrand disease and the hemophilias1 [1]. Prevalent etiologies include 
deficiencies in the cofactors essential to proper coagulation, such as vitamins K and C [2, 3]. 
Even the smallest amount of improper coagulation can pose a major risk to health.  
Coagulation is intimately linked to cardiovascular health. Cardiovascular diseases, such 
as coronary heart disease, stroke, and deep vein thrombosis (DVT), constitute the leading cause 
of hospitalization and death in the United States [4]. Certain genetic variations in clotting 
proteins have been clinically shown to affect an individual’s susceptibly to cardiovascular 
disease [5]. In addition to changes in lifestyle and diet, the therapeutic modulation of coagulation 
could serve as a method in both the prevention and intervention against certain cardiovascular 
diseases. Advances in the coagulation field may also improve current medical testing and certain 
surgical practices [6]. Research into the protein-to-protein interactions of coagulation provides 
insight into a biochemical process that continues to affect the livelihood of millions.  
Although multiple, interrelated signals initiate thrombosis, the coagulation cascade can be 
generally divided into two mechanisms: the contact factor and tissue factor pathways. The tissue 
factor pathway predominates in vivo. Tissue factor (TF) while absent in the endothelium, is an 
                                                        
1 The Centers for Disease Control and Prevention estimate von Willebrand disease affects 1% of the population. The 
hemophilias affect 1 in 5,000 male births. Approximately 400 children are born with hemophilia each year. 
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integral membrane glycoprotein present in tissues of the brain, lung, blood vessel wall, and 
placenta. Extrinsic activation of coagulation occurs when injury allows plasma to contact cells 
expressing TF [7]. The pathway then proceeds with the combinatory interactions of twenty 
different coagulation factors to form a hard clot. Notably, monocytes and damaged endothelium 
within atherosclerotic plaques synthesize TF in the presence of multiple pro-inflammatory 
cytokines, such as tumor necrosis factor-α and interleukin1-β [8]. TF exposure and the 
subsequent activation of coagulation may cause rapid thrombotic blockage of blood vessels in 
the event of plaque rupture. Ergo, TF activation of thrombosis is consequently implicated in 
many cases of myocardial infarction, stroke and DVT [9]. The less critical contact factor 
pathway involves factor XII activation and couples with signals from the tissue factor pathway. 
Both pathways converge at the multistep conversion of prothrombin (II) to α-thrombin (IIa).  
 
              
Figure 1: Coagulation consists of the contact factor and tissue factor pathways, which converge 
to form a prothrombinase complex (FVa-FXa). FVa-FXa generates IIa from prothrombin. Various 
steps are dependent on Ca2+, phospholipid (PL), and high-molecular-weight kininogen (HK).  
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As demonstrated by Figure 1, the coagulation cascade proceeds with the interactions of 
multiple coagulation factors. With the exception of fibrinogen and factor XIII (FXIII), the 
coagulation factors consist of multiple serine proteases. Sequence homology suggests most of the 
coagulation proteases may have arisen from a series of gene duplications [10]. Additionally, 
clotting proteases demonstrate active site homology with many pancreatic serine proteases 
involved in digestion, such as chymotrypsin, trypsin, and elastin. The activation of both digestive 
and clotting proteases requires the cleavage of a N-terminal propeptide, which further supports 
an evolutionary relationship between the two pools of serine proteases. While similarities exist 
between digestive proteases and many coagulation factors, both groups of enzymes appear to be 
regulated differently. Differential forms of regulation allow both groups of proteases to operate 
appropriately within a specific physiological environment.  
Proper coagulation culminates in the timely formation of an ample blood clot; therefore, 
the cascade involves multiple levels of regulation to prevent inappropriate thrombosis. Unlike 
the serine proteases involved in digestion, many of the clotting factors are fully activated only in 
the presence of Ca2+ and an anionic phospholipid surface. [11]. Anionic phospholipids, such as 
phosphatidylserine (PS) and phosphatidylethanolamine (PE), are nearly exclusive to the 
cytofacial leaflet of the plasma membrane [12]. Exposure of an anionic phospholipid surface 
occurs predominately during injury. Consequently, anionic phospholipid can attract plasma Ca2+.  
Multiple clotting factors contain one or more γ-carboxyglutamate (Gla) binding domains that 
then chelate Ca2+ ions with high affinity [2, 3].2 In this way, the anionic surface serves as an 
electrostatic docking station to collect multiple clotting factors and orients coagulation at a site of 
                                                        
2 A vitamin K dependent posttranslational modification converts glutamate residues into γ-carboxyglutamate (Gla) 
residues within Gla domains of a proenzyme. Gla domains chelate Ca2+.  
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injury. Additionally, concise modulation of Ca2+ levels in plasma can further control the extent of 
activation and propagation of the cascade.  
The formation of a blood clot is immediately dependent on the activation and interaction 
of three coagulation factors: prothrombin, FXIII, and fibrinogen. In the first of two steps to form 
a thrombus, activated thrombin (IIa) cleaves two anionic N-terminal fibrinopeptides (A and B) 
from fibrinogen to form fibrin monomers [13]. Noncovalent agglomeration of multiple 
monomers forms a fragile clot of protofibrils. Secondly, activated FXIII mediates the covalent 
crosslinking of fibrin monomers to effectively convert the soft clot into a hard thrombus. The 
integrity of the resulting thrombus depends on multiple factors. Rate of crosslinking and 
incorporation of anticoagulants, such as α2-antiplasmin, have been experimentally shown to 
affect clot structure [14]. Given the intricate activation and interaction of these three critical 
factors, regulation must be equally as efficient to ensure immediate and proper thrombosis.  
Prothrombin is a 579-residue zymogen present in the blood at 100 µg/mL (1.388 µM). 
Human prothrombin consists of three general domains: a large N-terminal propeptide, a 36-
residue A chain, and a 259-residue catalytic B chain. The N-terminal propeptide, released upon 
prothrombin activation, is further composed of a Gla domain and two kringle domains in tandem. 
A single disulfide bond persistently links the A and B chains together throughout a multistep 
activation process [15]. Prothrombin activation in vivo begins with cleavage of the Arg 271 – 
Thr272 and Arg 320 – Ile 321 peptide bonds by the FVa-FXa prothrombinase complex in the 
presence of Ca2+ and anionic phospholipid. Prothrombinase cleavage facilitates the release of the 
propeptide and dissociation of activated thrombin from the phospholipid surface. Formed 
thrombin then autocleaves to trim 13 residues from the enzyme’s N-terminus to generate α-
thrombin (IIa) [16]. IIa proceeds to serve both coagulant and anticoagulant roles.  
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An important role of IIa is to convert fibrinogen to fibrin. Human fibrinogen is a 340-kDa 
plasma glycoprotein that circulates within the blood at 2.0-4.0 mg/mL. Structurally, fibrinogen is 
a dimer of trimers consisting of two 610-residue Aα chains, two 461-residue Bβ chains, and two 
411-residue γ chains. X-ray crystallography suggests the center regions of the α, β, and γ chains 
associate into a symmetric set of α-helical coiled-coils. Globular D domains hang at both ends of 
the molecule and a globular E domain sits between the coiled-coils [17]. Anionic fibrinopeptides 
(FpA and FpB) hang from the central E domain and prevent premature aggregation of the protein 
in circulation. Upon IIa cleavage of FpA and FpB, multiple non-covalent interactions between 
the D and E domains promote the agglomeration of the newly formed fibrin monomers [13].  
Fibrin formation also permits the release of the αC region of Aα fibrinogen (Fbg αC) 
from the E domain. Fbg αC contains specific residues used by activated FXIII to crosslink a 
reactive glutamine of one fibrin monomer with a reactive lysine of another fibrin monomer [18]. 
The γ chain is also crosslinked by FXIII, with γ-γ crosslinks forming faster than α-α crosslinks. 
FXIII activity also affects other characteristics of a thrombus in vivo, such as the retention of red 
blood cells within the linked fibrin network [19, 20].3 Therefore, FXIII activation and interaction 







Figure 2: Fbg αC are released upon IIa cleavage as fibrin agglomerates to form a soft clot.  
                                                        
3 Trapped red blood cell may account for up to half the weight of a thrombus in vivo.  
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The transglutaminase factor XIII (FXIII) presents in vivo as one of two zymogens. Platelets, 
monocytes, and multiple cells of the placenta express FXIII as a homodimer of two 731-residue 
A chains (FXIII A2). Inactive plasma FXIII circulates as a tetramer composed of the two 
aforementioned A chains in addition to two 641-residue B chains (FXIII A2B2). Both A subunits 
are composed of an activation peptide, a β-sandwhich domain, two β-barrel domains, and a 
catalytic center. FXIII B subunits bind FXIII A subunits with a Kd of 1.0 x10
-10 M and 1% of 
FXIII A2 exists in the free form [21]. The association of the A and B subunits appears to increase 
the half-life of FXIII A2B2 in circulation. While FXIII activity serves multiple roles, the enzyme 








Figure 3: (Left) An individual FXIII A subunit is composed of multiple domains. (Right) Two 
FXIII A subunits dimerize as indicated: activation peptides in purple, β-sandwhiches in blue, β-
barrels 1 in green, β-barrels 2 in yellow, and catalytic core in red. 
 
In plasma, IIa cleavage removes a 37-residue portion of the activation peptide to convert 
FXIII A2B2 to an FXIII A2′B2 intermediate. Experiments in X-ray crystallography show a 
subsequent Ca2+-dependent conformational change pushes both β-barrel domains away to expose 
and set up the FXIII active site [23]. Ca2+ also contributes to the release of each A subunit from 
the corresponding B subunit (FXIII A2
*). FXIII A2
* immediately proceeds to catalyze formation 
of ε-amino(γ-glutamyl)lysine isopeptide bonds between two fibrin monomers [24].  
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Figure 4: (Left) With platelet FXIII, IIa cleaves the activation peptide each monomer of FXIII 
A2. Ca
2+ ion converts FXIII A2′ to functional FXIII A2*. (Right) In plasma, after IIa cleavage, 
Ca2+ mediates the dissociation of FXIII A2′ from FXIII B2 and setup of the FXIII A2* active site.  
 
 FXIII-A2
* operates via a catalytic triad similar to those of the cysteine proteases [25]. 
 The transglutaminase mechanism of FXIII A2
* involves attack by the catalytic cysteine thiolate 
on the amide group of a reactive glutamine to form a thioester linkage. Ammonia is concurrently 
released. Subsequently, the thioester intermediate transfers the glutamyl unit to an amine to form 
an amide linkage. Implicit to this mechanism is the prediction that the protein presenting the 
reactive glutamine localizes preferentially within FXIII A2
* through some binding interaction 
[26]. Putative binding sites of FXIII have been restricted to the γ 390-396 and Aα 389-403 
segments of human fibrinogen [27].  
 
Figure 5: FXIII A2
* uses a cysteine protease-
like catalytic triad to link macromolecules. The 
catalytic C314 thiolate is stabilized by an 
electrostatic interaction with the imidazolium 
ion of H373. D369 is suspected to accept a 
hydrogen bond from H373. The reactive 
thiolate attacks a reactive Gln to form the 
thioester intermediate as shown to the right.  
  
The proposed FXIII binding site on Fbg Aα may facilitate interaction between Fbg αC 
and FXIIIa A2
*
 and/or enhance activation of FXIII. A binding study by Smith et. al suggests a 
segment of the Fbg αC242-424 truncation could play a regulatory role in either the activation of 
FXIII and/or the binding of a recombinant FXIII A2
* (rFXIII A2
*). Fbg αC242-424 wild type has 
  Platelet FXIII A2                                       Plasma FXIII A2B2 
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been shown to bind FXIII A2B2 with a Kd of approximately10 nM and to the rFXIII-A2
* with a 
Kd of 2.35 ± 0.09 µM [28], [26].  Studies indicate E396A mutagenesis decreased Fbg αC 242-
424 binding to a rFXIII-A2*. Further in silico calculations by Smith et al. predict salt bridge 
formation between Fbg αC E396 and R158 within the activation cleft of FXIII A2* facilitates 
enzyme docking.  Association of Fbg αC 242-424 E396 with FXIII is also predicted to cause 
downstream stabilization within Fbg αC that could further influence protein interaction.  
 No known study has been conducted to assess whether a mutation at Fbg αC 233-425 
E396 affects the FXIII A2
* crosslinking of the reactive glutamines within the Fbg αC 233-425 
truncation. Fbg αC 233-425 is expected to contain the same FXIII binding site within Fbg αC 
389-403 previously investigated by Smith et al [26]. The current work entails three reactivity 
studies used to compare an expressed Fbg αC 233-425 E396A mutant with the Fbg αC 233-425 
wild type. Strategies utilizing matrix-assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry and 1H-15N heteronuclear spin quantum coherence (HSQC) nuclear 
magnetic resonance (NMR) spectroscopy were employed to investigate effects of mutagenesis at 
Fbg αC 233-425 E396. With this study, the role of Fbg Aα E396 can be further understood. 
 
Figure 6: The primary sequence of Fbg αC 233-425 is shown above. The three reactive 
glutamines are depicted in red, while the glutamate proposed as critical to formation of the 
putative FXIII A2
* binding site (underlined) is shown in green.  











Specific Aims  
The αC region of human fibrinogen (Fbg αC) contains three reactive glutamine residues 
(Q237, Q328 and Q366) involved in FXIII A2
* crosslinking of the α-chains of fibrin [24]. 
Studies suggest, in addition to reactive glutamines, Fbg αC may contain certain amino acids that 
play a role in either FXIII enzyme-substrate interaction or activation. Previous experiments 
demonstrate that FXIII interacts with truncations of human fibrinogen αC, with Fbg αC E396 
potentially facilitating enzyme docking. The glutamyl residue at this position has been proposed 
to aid in electrostatic stabilization between Fbg αC and FXIII. Additionally, structural effects 
afforded by the residue are suggested to enhance FXIII activation and reactivity. To address 
these research issues, the following work entailed three reactivity studies to compare an 
expressed Fbg αC 233-425 E396A mutant against the Fbg αC 233-425 wild type. 
Primary Hypothesis: Fbg αC 233-425 contains a binding site within Fbg αC 389-402 that 
may modulate the ability of FXIII to crosslink αC Q237, Q328 and Q366.  
 
AIM I: The putative Fbg 𝛂C binding site Fbg 𝛂C 389-402 may facilitate enzyme-substrate 
interaction. Pre-activated FXIII-A2* would crosslink reactive glutamines of Fbg 𝛂C 233-425 
E396A with glycine ethyl ester slower than those of the Fbg 𝛂C 233-425 wild type.  
 
FXIII A2 was activated by IIa in the presence of Ca
2+. IIa was inhibited with PPACK 
before the introduction of GEE and Fbg αC 233-425  (WT or E396A).  
 
Transamidation of each reactive glutamine of Fbg αC 233-425 (Q237, Q238 and Q366) by 
pre-activated FXIII A2
* was quantitated by a previously designed MALDI-TOF mass 
spectrometry strategy [24]. 
 
AIM II: A complementary 2D 1H-15N HSQC NMR strategy was used to assess FXIII A2* 
crosslinking of Fbg 𝛂C 233-425 E396A with 15N-labeled glycine ethyl ester.  
 
Results from the 1H-15N HSQC NMR spectroscopy experiment were compared to findings 




AIM III: Fbg 𝛂C 389-403 may contribute to FXIII activation. FXIII A2 is proposed to take 
longer to activate in the presence of Fbg 𝛂C 233-425 E396A than in presence of the wild 
type. The rate of crosslinking of Q237 within the Fbg 𝛂C 233-425 E396A mutant with 
glycine ethyl ester is proposed to be slower than the rate observed for the wild type.  
 
IIa was introduced to a solution of FXIII A2, Fbg αC 233-425 (WT or E396A), glycine 
ethyl ester and Ca2+. Crosslinking before IIa inhibition with PPACK was monitored.   
 
Transamidation of Q237 within Fbg αC 233-425 (E396A / WT) by FXIII-A2* was 


























Materials and Methods 
Site-Directed Mutagenesis  
A single point mutation was inserted into a PGEX GST – Fbg αC 233-425 plasmid within 
XL1-Blue Supercompetent Escherichia coli cells (Agilent Technologies) by means of mutagenic 
DNA primers. DNA primers (Integrated DNA Technologies) were designed in accordance to the 
QuikChange II Site-Directed Mutagenesis Kit protocol. The amino acid substitution E396A was 
accomplished by a single nucleotide base change, GAG to GCG, at the codon coding for E396. 
Both mutagenic primers utilized are listed below: 
 
Fbg αC 233-425 E396A Coding Strand Primer:  
5’- CTGGGGCACATTTGAAGCGGTGTCAGGAAATG -3’ 
Fbg αC 233-425 E396A Template Strand Primer:  
5'- CATTTCCTGACACCGCTTCAAATGTGCCCCAGTCTGG -3' 
 
 E396A Coding Primer E396A Template Primer 
Nucleotide Length 32 bases 37 bases 
Molecular Weight 9969.5 g∙mol-1 11236.3 g∙mol-1 
Melting Temperature (TM) 65.6℃ 67.8℃ 
Mass Received 23.9 nmol 23.2 nmol 
 
PCR Amplification and XL-1 Blue Supercompetent Cell Transformation  
 A PCR reaction solution of 5.0 µL 10x PCR reaction buffer, GST- Fbg αC 233-425 
construct stock, 20 µg E396A Coding Primer, 22 µg E396A Template Primer and a dNTP mix 
were diluted to 50 µL with 39.0 µL of distilled H2O. The resulting reaction mixture was 
subjected to a round of PCR amplification in accordance to the QuikChange II Site-Directed 
Mutagenesis Kit protocol for a 5.646-kBase PGEX plasmid. After amplification, the reaction 
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was treated with 2.0 µL of 10 U/µL Dpn1 restriction enzyme to digest parental DNA plasmid. 
Transformation of XL-1 Blue Supercompetent cells onto ampicillin-infused LB agar plates was 
accomplished in accordance to the QuikChange II Site-Directed Mutagenesis Kit protocol. Cell 
colony growth was monitored for 18 hours while incubating plates at 37℃. Select colonies were 
chosen and liquid cultures were made with ampicillin.  
 
DNA Purification and Sequencing 
DNA extraction and purification from XL1-Blue Supercompetent small liquid cultures 
were conducted in accordance to the Plasmid DNA Purification QIAprep Spin Miniprep Kit 
protocol using a microcentrifuge. DNA concentration measurements were performed with a 
NanoDrop spectrophotometer at 260 nm. The obtained DNA samples were submitted for 
sequencing to the CGeMM DNA Facility Core at the University of Louisville’s Health Science 
Center. DNA confirmed to contain the mutation of interest was stored for future transformation 
of BL-21 Gold DE3 E. coli cells.  
 
BL-21 Gold DE3 Cell Transformation and Glycerol Cell Stocks 
 The transformation of BL-21 Gold DE3 E. coli cells was conducted over ice. 
Approximately 26 ng of mutated DNA was added to 100 µL of thawed BL-21 Gold DE3 cells. 
The solution was mixed and allowed to sit over ice for 30 minutes. The solution was subjected to 
a 45 second heat pulse in a 42℃ water bath. The reaction solution was incubated in 0.9 mL 
aliquot of a super optimal broth with catabolite suppression (SOC broth) for an hour before 
plating onto LB agar plates with ampicillin. The inoculated plates sat at 37℃ for 17 hours. 
Selected colonies were chosen for small culture incubation. Three small cultures were prepared. 
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An IPTG test was conducted to assess the prolificacy of each small culture. The fastest growing 
culture was selected to make glycerol stocks. Cell stocks were made by first aliquoting 100 µL of 
cooled, autoclaved 50% glycerol into a 1.5 mL tube. 100 µL of BL-21 Gold DE3 cell culture was 
added to each solution of glycerol. Stocks were mixed gently and frozen at -80℃. 
 
GST-Fbg 𝛼C233-425 E396A Expression, Extraction, and Purification  
Media for two starter cultures were prepared with sterile technique by combining 180 mL 
LB broth, 20 mL phosphate buffer, and 200 µL 100 mg/mL ampicillin into two 500 mL 
Erlenmeyer flasks. Media were inoculated with frozen BL21 Gold DE3 glycerol cell stock. The 
starter cultures were allowed to shake at 225 rpm at 37°C for 17 hours. Two large BL21 Gold 
DE3 cell cultures were then prepared. A 200 mL amount of autoclaved phosphate buffer was 
introduced to 1.8 L of terrific broth. 2.0 mL of 100 mg/mL ampicillin was then added. Cultures 
were shaken by hand. The BL21 Gold DE3 small cultures were introduced to large cultures using 
sterile technique. The two LB large cultures were incubated at 37°C with shaking at 225 rpm. 
Using a Cary 50 Bio UV-Visible spectrophotometer, simple scans were used to monitor cell 
growth as a function of time for both large cultures. Scans at 600 nm were taken in 1 cm 
colorless cuvettes until each culture measured an optical density between 0.6 and 0.7. Protein 
expression was then induced with 2.2 mL of 1.0 M IPTG. Induced cultures were allowed to 
shake at 180 rpm at 30℃ for 15 hours. A lower incubation temperature was used to slow protein 
synthesis and prevent intracellular toxicity.  
After incubation, the two large BL21 Gold DE3 cell cultures were divided evenly and 
balanced within six 500 mL Beckman centrifuge bottles. Cells were spun down in a Beckman 
JA-10 centrifuge rotor at 3317 g for 10 minutes at 4℃. The supernatants were decanted and 
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subsequently bleach treated. The resulting pellets were then suspended in 360 mL of an E. coli 
wash buffer. The suspension was divided equally among eight 50 mL VWR centrifuge tubes. 
Tubes were spun at 5000 g in an Allegra R-20 swinging-bucket centrifuge for 1 hour at 4℃. The 
supernatants were discarded and bleach treated. A total of eight E. coli cell pellets were frozen at 
-20C for future protein extraction.  
Cell pellets were suspended by transferring pellets with spatula to a 100 mL glass beaker 
containing 176 mL of PBS. An analytical wash using an additional 176 mL of PBS was done to 
increase yield. The cell suspension was allowed to spin at a low rpm for 30 minutes at room 
temperature. 1.76 mL 100 mg/mL lysozyme and 177.6 µL DTT were added via pipette to the 
spinning solution. The cell suspension was allowed to spin at a low rpm for another 30 minutes 
at ambient temperature. Protease inhibitors were added: 177.8 µL 2 mg/mL Aprotinin, 177.8 µL 
1 mM Pepstatin A, 444 µL 4M Leupeptin, and 0.138 g benzamidine were added into the cell 
suspension. The cell suspension was stirred at a low rpm at 4℃ for 30 minutes. The suspension 
was returned to room temperature before adding 444 µL 100 mM PMSF in DMSO and 898 µL 
10% sodium deoxycholate. The suspension mixed at room temperature for another 30 minutes.  
Next, 9.0 mL of 20% Triton X100 was quickly introduced to the solution as the mixing 
speed was increased. The detergent was allowed to mix for 5-10 minutes at room temperature. 
94.5 µL of 10 mg/mL DNase 1 and 945 µL 1 M MgCl2 were added to the suspension. The 
suspension was mixed for 10 minutes at a low rpm at 4℃. DNase 1 was quenched by scavenging 
Mg2+ with 2.29 mL of 0.5 M EDTA. The suspension was returned to room temperature.  
The final suspension was evenly decanted into six small round-bottom Beckman 
centrifuge tubes. Using a beam balance, the tubes were balanced to even out the rotor in the 
centrifuge. Tubes were spun down for 20 minutes at 14275 g in a Beckman JA-20 rotor at a 
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temperature of 4℃. A sticky, grey-green solution formed containing cell lysate. A streptomycin 
paste (2.0 g streptomycin sulfate and distilled H2O) was added to the supernatant to remove any 
remaining nucleic acids. The streptomycin-infused filtrate was again divided between six small 
round-bottom Beckman centrifuge tubes, balanced, and spun at 14275 g for 20 minutes at a rotor 
temperature of 4℃. A small pellet formed. Supernatants from each of the six round-bottom 
Beckman centrifuge tubes were decanted into a 0.45 µm polyethersulfone (PES) sterile filter 
(Cole-Parmer). The filtrate was then passed through a smaller 0.20 µm PES sterile filter.  
The resulting sample was loaded onto two 5.0 mL GST-HiTrap (GE Healthcare) affinity 
columns in tandem over seven hours via an AKTAprime fast protein liquid chromatography 
(FPLC) instrument. Columns contained the glutathione ligand coupled to Sepharose by reaction 
of the thiol group with oxirane groups made by epoxy-activation of the Sepharose matrix. The 
glutathione stationary phase binds to the GST (glutathione S-transferase) tags of fusion proteins 
with high affinity. Once the solution had successfully loaded onto the column, the fusion protein 
was cleaved with PreScission Protease4. Chromatographic elution after cleavage of the fusion 
protein by PreScission Protease produced a set of 2.0 mL fractions suspected to contain free Fbg 
αC 233-425 E396A. SDS PAGE and Western Blotting with an anti-GST HRP conjugate (GE 
Healthcare) were employed to check for GST contamination. Spectrophotometry at 280 nm with 
a molar attenuation coefficient of 41480 M-1s-1 estimated a total protein yield of 2.74 mg protein 
(0.685 mg protein per L culture). All nine fractions found to contain free Fbg αC 233-425 E396A 
were further concentrated into stock solutions using a VivaSpin centrifugal concentrator with 
molecular weight cut-off of 30 kDa. 
                                                        
4 PreScission Protease is a fusion protein of the human rhinovirus protease and GST that facilitates the specific 




AIM I: MALDI-TOF Mass Spectrometry 
FXIII A2 activation was conducted by incubating final concentration of 500 nM FXIII A2 
(ZymoGenetics) with 8.40 U/mL IIa and 4.0 mM CaCl2 for 10 minutes at 37℃. The activation 
reaction was subsequently quenched with 0.3 µM PPACK solution. Final assay concentrations of 
13.8 mM CaCl2, 17 mM glycine ethyl ester and 13.6 µM Fbg αC E396A were diluted to a total 
reaction volume of 350 µL with 39.6 µL of Tris reaction buffer (100 mM Tris-acetate, 150 mM 
NaCl, 0.1% PEG at pH= 7.40). Note that extra CaCl2 was added in the listed amount to 
completely counter the presence of phosphates from the Fbg αC E396A solution (1x PBS ≈ 12 
mM PO4
3-). Total reaction volume was 350 µL. The FXIII A2
* crosslinking reaction was 
incubated over two hours at 37℃. Time points were taken as needed and Ca2+ scavenged with 10 
mM EDTA before freezing at -80℃. 
 
A 6.0 µL aliquot of the reaction solution at each time point was mixed with 6.0 µL of 
chymotrypsin digest buffer (100 mM Tris-HCl, 10 mM CaCl2 at pH = 7.40) and GluC digest 
buffer (25 mM NH4HCO3 at pH = 7.80). To initiate the chymotrypsin digest, 1.10 µg 
chymotrypsin (dissolved in 1.0 mM HCl) was added to the mixture containing chymotrypsin 
digest buffer. The chymotrypsin digest was incubated at 25℃ for 1 hour. To initiate the GluC 
digest, 0.100 µg GluC was added to the reaction mixture containing GluC digest buffer. The 
GluC digest was incubated at 25℃ for 2 hours. Both digests were quenched with 2.0 µL 5% 
trifluoroacetic acid (TFA).  
Solution cleaning and plating was done according to the ZipTip (Millipore) procedure for 
MALDI-TOF MS analysis. Pipet tips containing C18 resins were initially rinsed with 4.0 µL 
acetonitrile thrice and equilibrated with 4.0 µL 0.1% TFA thrice. Digest samples were loaded 
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onto the resins with vigorous pipetting. Any unbound sample was rinsed off the resins with 5.0 
µL of 0.1% TFA four times. Digest samples were eluted into 6.0 µL of matrix with vigorous 
pipetting. For the chymotrypsin digests, 10 mg/mL α-Cyano-4-hydroxycinnamic acid (αCHCA) 
in equal parts acetonitrile, ethanol and 0.1% TFA was used. For the GluC digests, 7.0 mg/mL 
ferulic acid matrix in equal parts acetonitrile and 0.1% TFA was used. Both digests were spotted 
onto a methanol-washed, 100 well MALDI-TOF MS plate in 1.0 µL aliquots. The plate was 
loaded into a Voyager DE-Pro MALDI-TOF mass spectrometer (Applied Biosystems) equipped 
with a nitrogen laser at 337 nm. Samples were analyzed under a positive peptide reflector 












1H-15N HSQC NMR Spectroscopy 
FXIII A2 activation was done by incubating final concentrations of 800 nM FXIII A2 
(ZymoGenetics) with 21.0 U/mL IIa and 5.0 mM CaCl2 for 10 minutes at 37℃. The activation 
reaction was subsequently quenched with 0.26 µM PPACK. Reaction components were added to 
Figure 7: (Below) A mathematical representation of how FXIII A2
* 
crosslinking of a glutamine reactant to the glutamyl-GEE isopeptide 
product is monitored as a function of time. (Right) MALDI-TOF MS 
can monitor the decrease in intensity of the reactant peak as the 
intensity of the product peak increases.  
Peak Height Ratio Formula 
 
Reactant left = ΣR/(ΣR+ΣP) * [Peptide] 
 
ΣR = Σ height of reactant peak 
ΣP = Σ height of product peak 
Q Substrate – GEE (P) 
            Q Substrate (R) 
 20 
the existing solution and 140.15 µL of borate buffer (20 mM borate at pH = 7.40) at final 
concentrations of 13.25 mM CaCl2, 10 mM 
15N-labeled glycine ethyl ester and 40 µM Fbg αC 
E396A. Total reaction volume was 400 µL. The FXIII A2
* crosslinking reaction was incubated 
for 30 minutes at 37℃ before scavenging Ca2+ with 0.64 mM EDTA. Then, 40 µL of D2O was 
added and the final solution was immediately transferred into a Shigemi NMR tube. Solution pH 
was estimated to be 6.0 by subjecting a small aliquot to a litmus paper test. The NMR tube was 
placed in a Varian Inova 700 MHz NMR spectrometer, equipped with a triple-resonance HCN 
probe and Z-axis gradients, at 25℃. The sample was not spun.  
 
The reaction was subjected to a 1H-15N HSQC spectroscopy experiment to detect 15N-
labeled amides. A 1D study was set up with the following parameters: Z0 = 6512, phase = 20, 
power = 45, gain = 45, np = 2048, ss = 2, NT = 512, at = 0.146, sw = 7022.5, tof = -254.3, pw = 
7.40 and tpwr = 58. The 2D experiment was employed with the following parameter changes 
from the 1D experiment: ni = 64 and nt = 64.  
 
AIM III: MALDI-TOF Mass Spectrometry 
 
With AIM I, FXIII A2 was pre-activated and then the crosslinking reaction of Fbg 𝛼C 
E396A with GEE was monitored. By contrast with AIM 2, the FXIII A2 was activated in the 
presence of its substrates. Before activation, a final concentration of 500 nM FXIII A2 was 
initially incubated with 13.6 µM Fbg 𝛼C E396A and 17 mM GEE in the presence of 13.8 mM 
Ca2+ and 39.6 µL Tris buffer. FXIII activation was then conducted by adding IIa to solution at 
8.40 U/mL. Total reaction volume was 350 µL. The FXIII A2
* crosslinking reaction was 
incubated at 37℃ over 30 minutes. Multiple time points were taken as needed and immediately 
quenched with 10 mM EDTA before freezing at -80℃. A 6.0 µL aliquot of the reaction solution 
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at each time point was mixed with 6.0 µL of GluC digest buffer (25 mM NH4HCO3 at pH = 
7.80). To initiate the GluC digest, 0.100 µg GluC was added to the reaction mixture containing 
GluC digest buffer. The GluC digest was incubated at 25℃ for 2 hours. The digest was quenched 
with 2.0 µL 5% trifluoroacetic acid (TFA). An identical cleaning and spotting protocol was used 
to prepare samples for analysis by MALDI-TOF MS.  
 
Results 
Site-directed Mutagenesis and BL-21 Gold DE3 E. coli Stocks 
DNA sequencing confirmed mutagenesis of the PGEX GST – Fbg αC 233-425 plasmid 
within XL-1 Blue Supercompetent E. coli cells. PCR produced a sufficient amount5 of mutated 
plasmid to transform BL-21 Gold DE3 cells. Transformed cells were plated on LB agar with 
ampicillin. Liquid cultures infused with ampicillin were then inoculated with BL-21 Gold DE3 
colonies. An IPTG test assessed the prolificacy of each culture and the fastest-growing culture 
was used to make cell stocks.  BL-21 Gold DE3 cells containing DNA for GST – Fbg αC 233-
425 E396A were frozen in glycerol and stored at -80℃ for future protein expression.  
 
Expression and Purification of Fbg αC233-425 E396A  
 BL-21 Gold DE3 E. coli cells from a frozen glycerol stock were used to inoculate a large 
4.0 L culture infused with ampicillin. IPTG was used to induce protein expression. Extraction 
and affinity chromatography purified the GST – Fbg αC 233-425 E396A fusion protein as 
described in Materials and Methods. Chromatographic elution after cleavage of the fusion 
protein by PreScission Protease produced a set of 2.0 mL fractions suspected to contain free Fbg 
αC233-425 E396A. Protein content and purity of each fraction was assessed with SDS PAGE, 
Western blotting, and spectrophotometry.  
 SDS PAGE gels stained with Coomassie Brilliant Blue dye revealed bands aligned with 
the 25-kDa molecular weight marker (MW Fbg αC 233-425 E396A ≈ 20 kDa) (Figure 8). Both 
SDS PAGE and an anti-GST Western blot indicated no contamination by free GST or intact 
fusion protein in any of the collected Fbg αC 233-425 E396A fraction.  
                                                        
5 PCR amplification was assessed with 1% agarose gel electrophoresis. The agarose gel matrix was infused with an 
ethidium bromide stain for visualization under ultraviolet light.   
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Analysis of Expression and Purification of Fbg αC233-425 E396A  
                     
   
Figure 8: (Top Left and Right) 9 of 17 protein fractions collected reveal bands aligned with the 
25 kDa molecular marker on 15% T SDS PAGE gels stained in Coomassie Brilliant Blue R250 
solution. Note the MW Fbg αC 233-425 E396A ≈ 20 kDa. (Bottom Left) Aliquots of multiple 
steps throughout protein preparation were subjected to SDS PAGE.  
 
Spectrophotometry at 280 nm with a molar attenuation coefficient of 41480 M-1s-1 
estimated a total protein yield of 2.74 mg protein (0.685 mg protein per L culture). All nine 
fractions found to contain free Fbg αC 233-425 E396A were concentrated into stock solutions 
using a VivaSpin centrifugal concentrator with molecular weight cutoff of 30 kDa. The protein 
concentration of each stock solution was similarly assessed by spectrophotometry. Fbg αC 233-
425 E396A stock concentrations ranged from 18.0 µM to 88.3 µM of protein. A 25.0 µM Fbg αC 
233-425 E396A substock was made with 1X phosphate buffered saline before each mass 
spectrometry or NMR spectroscopy assay.  
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Assessment of Fbg αC 233-425 E396A with MALDI-TOF MS  
 Both chymotrypsin and GluC digests were performed6 on stock Fbg αC 233-425 E396A. 
MALDI-TOF MS assessed whether the fragments previously monitored to quantitate FXIII A2
* 
crosslinking of the Fbg αC 233-425 wild type could be detected to similar extents when using 
the Fbg αC 233-425 E396A mutant. Analysis revealed the same three peptide fragments appear 
after the GluC and chymotrypsin digests of Fbg αC 233-425 E396A and wild type [24]. An 
additional peptide that previously contained E396 in the wild type decreased by a mass expected 
after Gln to Ala mutation (2704. 78 in the wild type to 2647.78 Da in Fbg αC 233-425 E396A).  
  
Figure 9: MALDI-TOF MS on chymotrypsin (Left) and GluC (Right) digests detect individual 
peaks containing the three reactive glutamine residues under study. A one-hour chymotrypsin 
digest produces the 2446.55-Da peptide fragment containing Fbg αC 233-425 Q237. GluC 
digestion for two hours produces the 1347.94 and 1548.82-Da peptide fragments containing Fbg 
αC 233-425 Q366 and Q328, respectively. Before analysis by MS, digests were mixed with 
organic matrices: chymotrypsin with αCHCA and GluC with ferulic acid.  
 
Control on IIa Cleavage of Fbg aC 233-425 (E396A / WT) 
 The integrity of the reactivity experiments presented below relied on intact Fbg αC 233-
425. As a protease, IIa cleavage of full fibrinogen is limited to the removal of FpA and FpB. It 
was not known if IIa would show activity towards the Fbg αC 233-425 fragment. Unexpected 
cleavage of Fbg αC233-425 could reduce or eliminate the ability of Fbg αC 233-425 to interact 
                                                        
6 Both chymotrypsin and GluC are C-terminal endopeptidases with pH optimums near 7.80. Chymotrypsin cleaves 











with or serve as a substrate for FXIII A2
*. Results (not shown), when compared to a positive 
control, indicated IIa does not cleave Fbg αC 233-425 E396A to any detectable extent. 
 
AIM I: Fbg αC E396A and Rate of FXIII A2* Crosslinking of Reactive Glutamines 
A MALDI-TOF mass spectrometry assay determined the rate of pre-activated FXIII A2
* 
crosslinking of reactive glutamines within Fbg αC 233-425 E396A by monitoring the 
disappearance of un-crosslinked Fbg αC 233-425 E396A as a function of time (Figure 10). Data 
indicate FXIII A2
* crosslinked the reactive glutamines of Fbg αC 233-425 E396A with glycine 
ethyl ester. Additionally, FXIII A2
* appears to crosslink Fbg αC 233-425 glutamines at different 
efficiencies (237Q > 366Q ~ 328Q). Pre-activated FXIII A2
* crosslinked the reactive glutamines of 
Fbg αC 233-425 E396A at rates comparable to the rates seen with the wild type under identical 
conditions (Figure 11) [24].   
 
Figure 10: Pre-activated FXIII A2
* crosslinks reactive glutamines within Fbg αC233-425 E396A 
despite the substitution of E396 with a smaller, nonpolar alanyl residue. FXIII A2 was activated 
to FXIII A2
* by IIa in the presence of Ca2+. A PPACK quench preceded introduction of GEE and 
Fbg αC 233-425 E396A. Reaction aliquots were quenched with EDTA and frozen at -80℃ prior 




























Figure 11: Pre-activated FXIII A2
* crosslinks 
each reactive glutamine of the Fbg αC 233-
425 E396A mutant with GEE at rates 
comparable to those seen with Fbg αC 233-
425 WT under the same reaction conditions. 





AIM II: 1H-15N HSQC NMR to Monitor FXIII A2
* Crosslinking of Reactive Glutamines 
Preliminary work with a new 1H-15N HSQC NMR assay provided insight into a potential, 
complementary method to confirm results seen with MALDI-TOF mass spectrometry. Previous 
studies on the Fbg αC 233-425 wild type show the FXIII A2* crosslinking of each reactive 
glutamine with 15N-labeled glycine ethyl ester produces an individual signal when probed by 1H-
15N HSQC NMR spectroscopy [24]. Results show FXIII A2
* crosslinks Fbg αC 233-425 E396A 
with 15N-labeled glycine ethyl ester under identical conditions (Figure 12). 1H-15N HSQC NMR 
produced three amide signals centered at (8.18 ppm, 113.75 ppm), (8.20, 113.75), and (8.35, 
113.95). The resonances correspond to the products of Q366, Q328 and Q237, respectively.  
Digests of the 1H-15N HSQC NMR solution were subjected to MALDI-TOF MS analysis 
both 24 hours and 5 days after the initial NMR experiment. Notably, the FXIII A2
* crosslinking 
of both Fbg αC 233-425 E396A Q328 and Q366 appears to continue (Figure 13). These results 
potentially question the efficacy of the EDTA quench applied during the original 1H-15N HSQC 
NMR experiment. More work is required to investigate this potential issue.  
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Figure 12: (Left) FXIII A2
* transamidation between a reactive glutamine and 15N-labeled glycine 
ethyl ester. The 15N isotope remains in the isopeptide product. (Right) The 1H-15N HSQC NMR 
spectrum after pre-activated FXIII A2
* crosslinked Fbg αC 233-425 E396A with 15N-labeled 
glycine ethyl ester for 30 minutes.  
 
 
Figure 13: FXIII A2
* crosslinking of Fbg αC 233-425 E396A with 15N-labeled glycine ethyl ester 
appears to proceed over time despite an EDTA quench applied the same day as an original 1H-
15N HSQC NMR experiment.  
 
AIM III: Fbg αC E396 and the Activation of FXIII A2*  
 Modulation of the original MALDI-TOF MS assay permitted further investigation of the 
Fbg αC 233-425 E396A mutant. FXIII A2 was incubated with Fbg αC 233-425 (E396A / WT), 
glycine ethyl ester, and Ca2+ before IIa activation. The rates of initial FXIII A2
* crosslinking of 
Q237 of both Fbg αC 233-425 E396A and the wild type were assessed and compared in a similar 
fashion as in AIM I (Figure 14). Given FXIII A2











































ethyl ester faster than both Fbg αC 233-425 Q328 and Q366, monitoring the rate of Q328 and 
Q366 crosslinking became too difficult at lower time points. Consequently, only Fbg αC 233-
425 Q237 has been presented. Results show FXIII A2, when incubated with its substrates, 
activates and subsequently crosslinks Q237 of Fbg αC 233-425 E396A and the wild type with 
glycine ethyl ester with similar efficiency.  
 
Figure 14: FXIII A2
* crosslinks Q237 of both Fbg αC 233-425 E396A and the wild type with 
similar efficiencies. FXIII A2 was incubated with Fbg αC 233-425 (E396A / WT) and glycine 
ethyl ester before IIa activation in the presence of Ca2+. Reaction aliquots were quenched with 
EDTA and freezing at -80℃ before digestion and MALDI-TOF MS to quantitate crosslinking. 









































Q237 Fbg aC E396A
Q237 Fbg aC WT
Q237 Fbg αC E396A 




Coagulation is the body’s first reaction to any damage to blood vessels, such as a wound 
or an internal rupture of a blood vessel. Given the intricacy of the coagulation cascade, the 
regulation of the numerous clotting factors must be equally as efficient to ensure immediate and 
proper thrombosis. In addition to bleeding disorders, such as von Willebrand disease and the 
hemophilias, the effects of abnormal coagulation contribute to many other disorders affecting the 
circulatory system. Congenital deficiencies of anticoagulants, such as antithrombin, protein C, 
and protein S, have been correlated with increased risk of venous thrombosis [29]. Results of 
epidemiological studies suggest plasma levels of fibrinogen and FVII are predictive of coronary 
heart disease [30]. Given the growing global burden of cardiovascular diseases, research into the 
intricacies of coagulation and thrombosis may provide insight for prevention and intervention 
against disorders of the cardiovascular system.  
Thrombogenesis in vivo culminates in the interaction of FXIII with fibrin(ogen). While 
much remains unknown of how these two clotting factors cooperate in vivo, published studies on 
the interaction between FXIII and fibrin(ogen) support FXIII binding onto fibrin(ogen) [28]. The 
early findings of Greenburg and Shuman demonstrated fibrinogen binds to plasma FXIII A2B2 
with a Kd of 10 nM. Results also indicated FXIII A2B2 remained bound with a similar affinity to 
the resulting fibrin monomer after IIa cleavage of fibrinogen FpA and FpB [28].  
Procyk et al. first localized a binding site for FXIII A2
* within fibrin Aα 389-402 using 
an antibody study. The binding of fibrin to placental FXIII A2
* was assessed in the presence of 
multiple antibodies, including anti-γ 392-406, anti-Bβ 15-21, and anti-Aα 389-402. The anti-Aα 
389-402 antibody substantially decreased FXIII A2
* binding to fibrin. Antibodies against the Bβ 
and γ chains of fibrin did not affect the binding interaction [31]. Results by Procyk et al. were in 
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agreement with previous findings of Credo et al, which indicated fibrin Aα 242-424 enhanced 
the binding of FXIII A2
* activated from FXIII A2B2 [32]. While studies proposed a new FXIII 
A2
* binding site within the αC region of fibrinogen Aα, further investigation into the specific 
binding interaction between FXIII A2
* and fibrinogen αC was required.  
Smith et al. further characterized the interaction between FXIII and fibrin(ogen) αC [26]. 
Methods in surface plasmon resonance (SPR) using recombinant truncations of Fbg αC 233-425 
confirmed the previously described FXIII A2
* binding site within Fbg αC 389-403. In agreement 
with the observations of Procyk et al [31], Smith et al. demonstrated Fbg αC 389-403 bound a 
cleft of the β-sandwich domain of FXIII A2* exposed in the presence of Ca2+ after IIa cleavage of 
the FXIII activation peptide [23]. A multiple sequence alignment (MSA) of fibrin(ogen) αC 371-
425 in seven species identified conserved residues within fibrin(ogen) αC 389-403. SPR studies 
on a series of mutant Fbg αC 389-403 peptides revealed an E396A mutation substantially 
decreased the binding of FXIII A2
* to the Fbg αC 389-403 peptide. In silico calculations using X-
ray crystallography data predicted Fbg αC E396 may participate in an electrostatic interaction 
with R158 within the activation cleft of FXIII A2
* [23].  Authors proposed that structural effects 
caused by a salt bridge between Fbg αC E396 and FXIII A2* facilitates the observed binding.  
An enzyme-linked immunoabsorbant assay (ELISA) and a FXIII A2
* 5-(biotinamido) 
pentylamine incorporation assay conducted by Smith et al. investigated the inhibitory effect of a 
synthetic Fbg αC 389-402 E396A peptide on the interaction between Fbg αC and FXIII A2* [26]. 
Results demonstrated a synthetic Fbg αC 389-402 E396A peptide failed to inhibit binding of 
FXIII A2
* to Fbg αC 233-425. Consequently, binding of the peptide to FXIII A2* did not 
interrupt FXIII A2
* crosslinking of an biotinylated glutamine donor with either poly-L-lysine or 
the reactive K303 residue of fibrin monomers. The collective work by Smith et al. on Fbg αC 
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233-425 and the Fbg αC E396 residue would predict an E396A mutation within a recombinant 
Fbg αC segment should cause decreased association and reactivity of FXIII A2* [23, 26]. The 
work presented herein assessed the effect of the E396A mutation within Fbg αC 389-402 on the 
crosslinking of three natural substrates (Fbg αC Q237, Q328, and Q366) by FXIII A2*.  
Results of three reactivity studies indicate mutation at Fbg αC E396 does not affect FXIII 
A2
* reactivity towards the three reactive glutamines of Fbg αC 233-425. Complementary assays 
utilizing MALDI-TOF mass spectrometry and 1H-15N HSQC NMR spectroscopy confirm FXIII 
A2
* crosslinked Fbg αC 233-425 E396A with glycine ethyl ester. Additionally, pre-activated 
FXIII A2
* was shown to crosslink the three reactive glutamines of Fbg αC 233-425 E396A at 
rates comparable to the rates previously seen with the wild type under identical conditions [24]. 
These results question the extent to which the interactions proposed by Smith et al. between Fbg 
Aα and FXIII influence the reactivity of FXIII A2* towards Fbg αC Q237, Q328, and Q366.  
A second MALDI-TOF mass spectrometry assay revealed FXIII A2, when incubated with 
its substrates, activates and subsequently crosslinks Q237 of Fbg αC 233-425 E396A and the 
wild type with glycine ethyl ester at similar rates. When taken together, the three studies 
presented indicate the loss of Fbg αC E396 does not influence either activation of FXIII A2 to 
FXIII A2
* or the ability of FXIII A2
* to recognize and bind to Fbg αC 233-425. Given the 
information presented, results could be interpreted two different ways. Firstly, if Fbg αC E396 
contributes to a putative FXIII binding site, the electrostatic interaction proposed by Smith et al. 
between Fbg αC E396 and FXIII A2* R158 must not be required for the proper transglutaminase 
activity of FXIII A2
* [23]. Alternatively, additional structural details of the natural Fbg αC 233-
425 segment must exist to successfully compensate for the loss of Fbg αC E396 to FXIII A2* 
R158 interaction and any consequential structural changes. 
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In addition to documenting interactions of FXIII A2
* and Fbg 𝛼C 233-425, Smith et. al 
have identified a high-affinity interaction between FXIII A2B2 and Fbg 𝛼C 371-425 [26]. FXIII 
A2B2 binding to Fbg αC appears to occur before and after IIa cleavage of the FXIII activation 
peptides. Future work should assess whether the presence of FXIII B2 subunits target this 
putative FXIII binding site of Fbg Aα to modulate either FXIII A2B2 activation or reactivity 




















Three reactivity experiments indicate an E396A mutation within Fbg αC 233-425 does 
not influence either the activation of FXIII A2 to FXIII A2
* or the ability of FXIII A2
* to 
recognize and bind Fbg αC 233-425. Although Fbg αC E396 contributes to a putative FXIII 
binding site, a proposed interaction between Fbg αC E396 and FXIII A2* R158 is not required 
for the proper transglutaminase activity of FXIII A2
*. Alternatively, additional structural 
components of the natural FXIII A2 substrate, Fbg αC 233-425, could exist to compensate for the 
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